Login to Your Account

Nektar Coffers Brimming with Cash Thanks to $1.5B Deal

By Catherine Hollingsworth

Tuesday, September 22, 2009
Nektar Therapeutics Inc. will end the year flush with cash, after entering a deal valued at $1.5 billion with AstraZeneca plc. to develop a late-stage bowel drug candidate and a preclinical pain product. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription